Fortress Biotech Inc (FBIO) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

squiggleburp Aug. 7 at 11:09 PM

$FBIO Please feel free to direct, correct or erect me if I am wrong! Okay so, we have upcoming earnings that may give us a better idea of what’s happening and what to expect. August 12 I believe. As far as the share price, High Beta stock, moves with the market. Technically, Previous support levels around $1.80–$1.85 have not held, and the stock has repeatedly failed to bounce convincingly from these zones. • This suggests seller dominance and a lack of institutional accumulation. 4. Bearish Moving Averages • The 50-day and 200-day moving averages are both: • Sloping downward • Positioned above the current price • This implies a longer-term downtrend, with possible resistance forming at those levels during any rebound attempts. There also seems to be a complex partnership. I don’t friggen know, or do eye?

1 · Reply

thesaltier1 Aug. 7 at 2:59 PM

$FBIO $DERM saw news on them ringing the closing bell the day before they announce earnings. I can't imagine they get all the positive attention for ringing the bell only to tank earnings the next day

1 · Reply

Waters59 Aug. 7 at 1:59 PM

$FBIO What is with this stock. For a yr it hits $2 with a selloff then back down to $1.40-$1.50 buy then back to $2 for another selloff. Manipulated much? This should be rolling to $6 by now based on the moves and the money this company has generated over last 3 months. What is holding this back?

1 · Reply

squiggleburp Aug. 6 at 10:02 PM

$DERM $FBIO FBIO- PDUFA September 30! DERM- earnings next week. Straight trajectory North!Still room? FBIO has my eye. Only one because they are crossed. I am interested and started to dig! Anything to know?

0 · Reply

Zellchair Aug. 6 at 10:48 AM

$FBIO $FBIOP There is absolutely nothing to see here... https://finance.yahoo.com/news/menkes-disease-market-analysis-forecast-131400555.html https://www.researchandmarkets.com/reports/6096996/menkes-disease-market-global-regional

0 · Reply

Zellchair Aug. 6 at 10:19 AM

$FBIO $FBIOP "Novo Nordisk's Knudsen: Balance sheet strong for acquisitions - We have one of the lowest debt ratios in pharma... So just by using our balance sheet, we have very significant firepower, Knudsen says." If only there was something they could buy to broaden their pipeline... https://www.bloomberg.com/search?query=novo%20nordisk

0 · Reply

Sawnchey Aug. 6 at 9:20 AM

$DERM $FBIO $FBIOP I am going to mention amother stock here, it's not to plug, but to give context to my thoughts on DERM. The most successful launch story I have been following this past year is MDGL. They have different circumstances, but their approach and focus closely mirrors what I hear and like from Journey. MDGL were first to market with their product, it's a blockbuster indication for MASH. Their US sales went as follows: Q2 2024 - 15m Q3 2024 - 62m Q4 2024 - 103m Q1 2025 - 137m Q2 2025 - 213m The scale of revenue is different, but they (like Journey) took a diligent approach to product education, market access and broad publication of data. With Journey, I am seeing a similar pace of payor coverage, dissemination of their excellent clinical data, and from day 1 they had an experienced sales force with existing relationships with prescribers. Q2 figures may not be enormous, but I am expecting steady growth quarter-on-quarter. Plus they only need about 4m to reach profit.

0 · Reply

Zellchair Aug. 6 at 8:53 AM

$FBIO $FBIOP SOT? WITHDRAWN https://clinicaltrials.gov/study/NCT06133010 Of all the indications Triplex is currently being studied, only the smallest indication, HCT, remains for mRNA-1647 (congenital CMV infection different story but Triplex is not in any studies there). And there, in HCT, Moderna is years behind Triplex, even if they were to present positive P2 data... https://clinicaltrials.gov/study/NCT05683457

1 · Reply

Zellchair Aug. 6 at 8:40 AM

$FBIO $FBIOP HHS & FDA is watching you mRNA-1647! The entire Helocyte/Triplex wave is heading towards a potential incredible dream scenario within HCMV. A 50-60 year marathon where all competitors drop out while your energy and strength just continue to be confirmed along the way with a little bit left to the finish line... https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html https://x.com/SecKennedy/status/1952851097019633766

0 · Reply

Zellchair Aug. 6 at 6:06 AM

$FBIO $FBIOP "What Are Common Oral Medications For Rosacea?" Not unexpectedly, the answer in the future seems to be EMROSI from $DERM https://www.youtube.com/watch?v=-5r1bcxEOKY

0 · Reply

Market Cap	55.59M
Revenue (ttm)	57.68M
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-79.75%
Debt to Equity Ratio	1.74

Volume	95,965
Avg Vol	209,468
Day's Range	N/A - N/A
Shares Out	29.57M
Stochastic %K	36%
Beta	1.76
Analysts	Strong Sell
Price Target	$15.33